The biopharmaceutical company vTv Therapeutics (NASDAQ: VTVT) was in focus in the markets yesterday after the company made a major announcement with regards to its business.
Following the announcement, the stock soared and went up by as much as 34% as investors piled onto the stock. On Tuesday it emerged that the United States Food and Drug Administration awarded breakthrough drug designation to its product TTP 339. The product in question is supposed to work with insulin in order to treat people suffering from Type 1 diabetes.
It is one of the most important products in the company’s portfolio and hence, it is no surprise that investors have welcomed the news with great enthusiasm. It should be noted that vTv is a relatively small company and as of yesterday, it commanded a market cap of only $200 million. It should also be noted that vTv also expects to make more applications in the future in relation to products in its pipeline.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life